

Phase II Clinical Trial of KJ101 in the Treatment of Deep II Degree Burns

NCT07025408

Status	RECRUITING
Phase	Phase 2
Sponsor	Shanghai Bao Pharmaceuticals Co., Ltd.
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (3)

- Male and female subjects aged 18 to 65 years inclusive, who are neither pregnant nor lactating;
- Clinically diagnosed with superficial or deep II degree burns within 72 hours of injury, with a total burn area of $\geq 30\%$ TBSA. The target burn wound must be isolated or have distinguishable boundaries, with an area between 40 and 200 cm².
- Subjects of childbearing age must agree to use effective and safe contraceptive methods during the treatment period and for three months after the final administration.

Exclusion (6)

- Individuals who are known to be allergic to any component of the test drug or who have a tendency to allergies.
 - Burns caused by specific factors, such as electrical or chemical burns.
 - Subjects with shock or inhalation lung injury;
 - Subjects with target wounds complicated by inflammatory skin diseases (e.g. atopic dermatitis, eczema or psoriasis), or who have undergone enzymatic debridement (e.g. with collagenase, papain, bromelain, chymotrypsin or trypsin).
 - Subjects who, during screening, are judged by the investigator to have other severe systemic infections requiring systemic treatment;
- ... and 1 more (see full listing online)

Locations (1 total)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China